PromarkerD predicts risk of DKD in Aboriginal Australians
Filed with ASX · · 3 pages · English
• PromarkerD shows acceptable and clinically meaningful predictive accuracy for diabetes-related chronic kidney disease (DKD) in Aboriginal people with diabetes • Peer-reviewed study published overnight in the Internal Medicine Journal shows no statistically significant difference in test performance between Aboriginal and non-Aboriginal participants • High negative predictive value (>85%) support
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Response to ASX Price Query
- US Medicare sets reimbursement price for PromarkerD DKD test
- OxiDx test correlates with superior racehorse performance
- Proteomics International receives $2.2m in R&D tax incentive
- PromarkerEndo test for endometriosis receives $0.5m grant
Later from Proteomics International Laboratories
- US patent secured for PromarkerEso diagnostic test for EAC
- Proteomics US lab CAP accredited - extends precision Dx lab
- Appointment of CEO and Managing Director
- Canadian patent secured for PromarkerEso test for EAC
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories